Palo Alto Investors LP
An institutional investment manager in PALO ALTO, CA. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 19, 2026. SEC CIK 1306923.
- Reported value$723.7m
- Positions52
Holdings: 52 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| PTC Therapeutics IncPTCT | COM | 69366J200 | 75.0 | 10.4% | 918,846 | Reduced−2,761 | |
| Acadia Pharmaceuticals IncACAD | COM | 004225108 | 72.5 | 10.0% | 2,864,096 | Reduced−8,599 | |
| Insmed IncINSM | COM PAR $.01 | 457669307 | 44.1 | 6.1% | 413,980 | Reduced−1,289 | |
| Mirum Pharmaceuticals IncMIRM | COM | 604749101 | 40.8 | 5.6% | 348,808 | Added+23,633 | |
| Anaptysbio IncANAB | COM | 032724106 | 40.7 | 5.6% | 603,489 | Reduced−34,672 | |
| Biomarin Pharmaceutical IncBMRN | COM | 09061G101 | 39.1 | 5.4% | 682,777 | Reduced−2,405 | |
| Dyne Therapeutics IncDYN | COM | 26818M108 | 36.6 | 5.1% | 1,647,521 | Reduced−5,451 | |
| United Therapeutics CorpUTHR | COM | 91307C102 | 33.9 | 4.7% | 62,587 | Reduced−222 | |
| Disc Medicine IncIRON | COM | 254604101 | 30.5 | 4.2% | 416,646 | Added+14,927 | |
| Biogen IncBIIB | COM | 09062X103 | 30.3 | 4.2% | 140,279 | Reduced−440 | |
| Iovance Biotherapeutics IncIOVA | COM | 462260100 | 22.0 | 3.0% | 5,296,209 | Reduced−1,053,354 | |
| Ultragenyx Pharmaceutical inRARE | COM | 90400D108 | 19.9 | 2.8% | 596,495 | Unchanged | |
| Novocure Ltd | ORD SHS | G6674U108 | 19.4 | 2.7% | 1,280,439 | Unchanged | |
| Syndax Pharmaceuticals IncSNDX | COM | 87164F105 | 18.9 | 2.6% | 864,986 | Unchanged | |
| Annexon IncANNX | COM | 03589W102 | 16.8 | 2.3% | 2,948,090 | Unchanged | |
| Bicara Therapeutics IncBCAX | COM | 055477103 | 16.3 | 2.3% | 550,408 | Unchanged | |
| Caredx IncCDNA | COM | 14167L103 | 15.2 | 2.1% | 531,870 | Unchanged | |
| Celldex Therapeutics IncCLDX | COM NEW | 15117B202 | 14.9 | 2.1% | 399,856 | Added+103,448 | |
| Compass Therapeutics IncCMPX | COM | 20454B104 | 12.8 | 1.8% | 5,831,813 | Added+4,317,309 | |
| Alkermes plc | SHS | G01767105 | 12.7 | 1.8% | 242,560 | Unchanged | |
| First Tracks BiotherapeuticsTRAX | ORD SHS | 337185102 | 12.1 | 1.7% | 603,489 | New+603,489 | |
| Prothena Corp plc | SHS | G72800108 | 11.2 | 1.5% | 1,143,155 | Reduced−65,413 | |
| Travere Therapeutics IncTVTX | COM | 89422G107 | 9.5 | 1.3% | 167,525 | Reduced−62,928 | |
| Taysha Gene Therapies IncTSHA | COM SHS | 877619106 | 9.5 | 1.3% | 1,391,382 | Unchanged | |
| Aclaris Therapeutics IncACRS | COM | 00461U105 | 8.5 | 1.2% | 1,613,430 | Unchanged | |
| Agios Pharmaceuticals IncAGIO | COM | 00847X104 | 7.9 | 1.1% | 213,601 | Unchanged | |
| Capricor Therapeutics IncCAPR | COM NEW | 14070B309 | 5.5 | 0.8% | 229,763 | Unchanged | |
| Align Technology IncALGN | COM | 016255101 | 5.3 | 0.7% | 31,389 | Reduced−10,131 | |
| ORUKA THERAPEUTICS INC - RestrictedORKA | COM | 687604108 | 3.2 | 0.4% | 33,546 | Reduced−26,439 | |
| Xenon Pharmaceuticals IncXENE | COM | 98420N105 | 3.1 | 0.4% | 51,345 | Unchanged | |
| Neurocrine Biosciences IncNBIX | COM | 64125C109 | 3.1 | 0.4% | 18,117 | Unchanged | |
| Edwards Lifesciences CorpEW | COM | 28176E108 | 3.0 | 0.4% | 33,640 | Unchanged | |
| Stoke Therapeutics IncSTOK | COM | 86150R107 | 2.8 | 0.4% | 84,631 | Unchanged | |
| Cytokinetics IncCYTK | COM NEW | 23282W605 | 2.7 | 0.4% | 32,195 | Unchanged | |
| Pyxis Oncology IncPYXS | COMMON STOCK | 747324101 | 2.6 | 0.4% | 864,277 | Reduced−146,233 | |
| Ehealth IncEHTH | COM | 28238P109 | 2.2 | 0.3% | 1,482,797 | Unchanged | |
| Crispr Therapeutics AG | NAMEN AKT | H17182108 | 2.2 | 0.3% | 39,605 | Unchanged | |
| Sagimet Biosciences Inc-ASGMT | COM SER A | 786700104 | 1.9 | 0.3% | 250,000 | New+250,000 | |
| Nuvation Bio IncNUVB | COM CL A | 67080N101 | 1.9 | 0.3% | 326,609 | Reduced−182,237 | |
| Biontech Se-AdrBNTX | SPONSORED ADS | 09075V102 | 1.8 | 0.3% | 19,614 | Unchanged | |
| Compass Pathways plc AdrCMPS | SPONSORED ADS | 20451W101 | 1.6 | 0.2% | 115,616 | Unchanged | |
| Humana IncHUM | COM | 444859102 | 1.6 | 0.2% | 3,985 | Unchanged | |
| Newamsterdam Pharma Co NV | ORDINARY SHARES | N62509109 | 1.5 | 0.2% | 44,359 | New+44,359 | |
| Verastem IncVSTM | COM NEW | 92337C203 | 1.2 | 0.2% | 309,685 | Added+63,592 | |
| Madrigal Pharmaceuticals IncMDGL | COM | 558868105 | 1.0 | 0.1% | 1,787 | Unchanged | |
| Urogen Pharma Ltd | COM | M96088105 | 0.9 | 0.1% | 24,500 | Unchanged | |
| Bicycle Therapeutics Plc-AdrBCYC | SPONSORED ADS | 088786108 | 0.9 | 0.1% | 201,890 | Unchanged | |
| Xeris Biopharma Holdings IncXERS | COM | 98422E103 | 0.8 | 0.1% | 104,410 | Unchanged | |
| Abeona Therapeutics IncABEO | COM NEW | 00289Y206 | 0.7 | <0.1% | 108,865 | Unchanged | |
| Inspire Medical Systems IncINSP | COM | 457730109 | 0.4 | <0.1% | 8,772 | Unchanged | |
| Proqr Therapeutics NV | SHS EURO | N71542109 | 0.4 | <0.1% | 188,807 | Unchanged | |
| Aldeyra Therapeutics IncALDX | COM | 01438T106 | 0.3 | <0.1% | 155,709 | Unchanged |
Sold out: 2 positions
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Amicus Therapeutics Inc | COM | 03152W109 | 0.0 | 0.0% | 0 | Sold out−1,113,045 | |
| Denali Therapeutics IncDNLI | COM | 24823R105 | 0.0 | 0.0% | 0 | Sold out−234,582 |
Source: SEC EDGAR, Form 13F-HR, accession 0002073679-26-000102 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.